Skip to main content

Table 2 Gene mutation rate for EGFR, ALK, KRAS, ROS1, RET and MET in four groups

From: Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma

 

mucinous

p

neuroendocrine

p

poor-differentiated

p

reference

total

EGFR

18.8%

(12/64)

***

20.0%

(8/40)

***

48.1%

(106/220)

 

52.4%

(418/798)

48.5%

(544/1122)

ALK fusion

17.1%

(11/64)

***

0%

(0/40)

-

7.2%

(16/220)

 

1.3%

(10/798)

3.3%

(37/1122)

KRAS

29.7%

(19/64)

***

5.0%

(2/40)

 

13.2%

(29/220)

*

3.0%

(24/798)

6.6%

(74/1122)

ROS1 fusion

0%

(0/64)

-

0%

(0/40)

-

2.7%

(6/220)

 

0.2%

(2/798)

0.7%

(8/1122)

RET

0%

(0/64)

-

0%

(0/40)

-

2.7%

(6/220)

 

0.8%

(6/798)

1.1%

(12/1122)

MET

1.6%

(1/64)

 

0%

(0/40)

 

4.6%

(10/220)

 

2.9%

(23/798)

3.0%

(34/1122)